Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson sees device slowdown in third quarter

This article was originally published in Clinica

Executive Summary

Competition from Boston Scientific in the drug-eluting stent market took its toll on Johnson & Johnson's medical device and diagnostic sales growth in the third quarter. Revenues rose by just 3.6% operationally, to $4bn - although positive currency effects helped boost reported growth to 7%. A year earlier, third-quarter growth was 16.3% operationally and 20.3% on a reported basis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel